- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03945864
Antimicrobial Synthetic Bone Grafts
The Use of Antimicrobial Synthetic Bone Grafts in the Treatment of Bone Infection
This project aims to produce synthetic bone tissue graft that supports bone regeneration and combats infection simultaneously, according to industry standards and regulations. This original and high value added biomaterial "silver doped calcium phosphate based synthetic bone tissue " will be used in clinical trials in patients with osteomyelitis and implant-related infections for the treatment.
Chronic bone infections are one of the most important problems in orthopedic surgery and are not just a problem of developed societies. When open fracture cases, which may get infected in 1-50%, implant-related infections and diabetic foot ulcer cases are taken into consideration, osteomyelitis will be seen as a very common problem all over the world. Multiple surgeries, long-term use of antibiotics and the high costs affects all societies. The use of synthetic bone grafts is growing faster than the natural bone grafts in the world. USA has spent 246 million US dollars for the use of synthetic bone graft in 2010. For the treatment of bone infections antibiotic impregnated synthetic bone grafts with different characteristics are used. Although these antibiotic impregnated synthetic bone grafts are superior compared to antibiotic bone cement with the implementation of different antibiotics and to be absorbable but they cannot show optimum benefit because the release of antibiotics is not due to host matrix degradation but diffusion control. The other issue to be considered as this regard that the development of microbial resistance to these antibiotics which is also a serious problem. Innovative synthetic bone graft with better contribution of the needs of mechanical properties, depending on the applied bone region, optimized antimicrobial activity and bone tissue regeneration are needed.
In this study, it will be determined whether this silver ion -doped antimicrobial synthetic bone graft that has the capacity to fill the bone voids that may occur in chronic bone infection during disease process or after surgical debridement, also has the capacity to treat the infection in the bone will be used in 12 patients who had been diagnosed as chronic osteomyelitis to see if it cause any unwanted side effect in normal usage conditions and generates unacceptable risks. Clinical, laboratory and radiological investigations will be used to demonstrate the healing of the infections and the cavities in the bone. Blood and urine levels of silver will be detected from patients.
Antimicrobial activity of silver is well-known. The effectiveness of the silver and potential toxicity is related to the dose of silver and application form. In orthopedics, the use of silver is mostly limited to elemental silver coating of metal implants. There is no biotechnologic approach manufactured silver ion -doped calcium phosphate -based synthetic bone graft in the health sector yet. Ionic silver has advantages such as low toxicity, no tolerance of silver against bacteria, and strong antibacterial activity. The trapping of silver ions in the calcium phosphate based ceramic structure overcomes the other systems with its controlled release and its ability to be effective at minimum doses. The project is an original work since it will contribute to bone regeneration while at the same time removing the infection.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Eskişehir, Turkey, 26480
- Eskişehir Osmangazi University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with chronic osteomyelitis, infected non-union or implant-associated infection with an indication for artificial bone grafting who read and accept the Informed consent.
- Male and female patients older than 18 years
- Patients without heart, lung, renal or hepatic failure, epilepsy, cerebrovascular attack or ischemia
- Patients who are not allergic to antibiotics
- Patients with additional immunosuppression such as malignancy, diabetes mellitus, poly travma and open fractures
- Patients using oral or parenteral corticosteroids, methotrexate, cyclosporine or other immunosuppressive drugs
Exclusion Criteria:
- Patients who have not accepted the method.
- Patients outside the working age range
- Pregnant women
- Patients with heart, lung, renal, hepatic failure, epilepsy, cerebrovascular attack or ischemia
- Patients with allergy to antibiotics
- Patients with another silvery implant in the body like a silver-coated implant
- Patients with a history of known allergies or hypersensitivity to silver
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: antimicrobial synthetic bone graft
This group will have parenteral antibiotics and antimicrobial (silver ions) synthetic bone graft
|
It will be determined whether the silver ion-doped antimicrobial synthetic bone graft that has the capacity to fill the bone voids also has the capacity to treat the infection in the bone in 12 patients with chronic osteomyelitis
|
Active Comparator: parenteral antibiotics with pure synthetic bone graft
This group will have parenteral antibiotics and pure synthetic bone graft
|
Historical data of the department will be used for comparison of the results
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
bony healing of the cavities in the bone
Time Frame: 12 months
|
Number of Participants with bony healing of the cavities in the bone by x-ray
|
12 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019-2491
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bone Infection
-
Robert Jones and Agnes Hunt Orthopaedic and District...Keele UniversityEnrolling by invitationProsthetic Joint Infection | Bone Infection | Prosthetic Infection | Bone TumoursUnited Kingdom
-
Academisch Ziekenhuis MaastrichtUniversity Medical Center GroningenActive, not recruitingOsteomyelitis | Bone Infection | Non-Union Fracture | Bone Infection of Lower Leg | Bone Infection of Pelvis, Hip, or Femur
-
Rigshospitalet, DenmarkInnovation Fund Denmark; The research foundation of Copenhagen University Hospital... and other collaboratorsActive, not recruitingOsteomyelitis | Septic Arthritis | Bone Infection | Joint Infection | Bone and Joint InfectionDenmark
-
Infectious Diseases Physicians, Inc.Johns Hopkins UniversityCompletedProsthetic Joint Infection | Osteomyelitis | Septic Arthritis | Bone Infection | Joint InfectionUnited States
-
Murdoch Childrens Research InstituteRecruitingOsteomyelitis | Septic Arthritis | Bone Infection | Bone and Joint InfectionNew Zealand, Australia
-
Lundquist Institute for Biomedical Innovation at...Paratek Pharmaceuticals Inc; Chapman UniversityRecruitingBone Infection | Joint Infection | Bone and Joint InfectionUnited States
-
AO Clinical Investigation and Publishing DocumentationCompletedStaphylococcus Aureus | Bone InfectionUnited States, Belgium, Denmark, China, Argentina, Germany, Japan, Switzerland, Austria, Canada
-
Hospices Civils de LyonCompletedBone and Joint InfectionFrance
-
AO Research Institute DavosCompletedFractures, Bone | Infection, Bacterial | Bone Infection | Joint InfectionSwitzerland
Clinical Trials on antimicrobial synthetic bone graft
-
Institut Straumann AGTerminatedTooth LossUnited States
-
Research and Education in DentistryUnknownTooth Abnormalities | Tooth InjuriesUnited Kingdom
-
Seoul National University HospitalUnknownOsteoarthritis, KneeKorea, Republic of
-
Johns Hopkins UniversityTerminatedEnd Stage Renal Disease | Hemolysis | Arteriovenous GraftUnited States
-
Mansoura UniversityUnknownVascular Access ComplicationEgypt
-
Spine WaveTerminatedDegenerative Disc Disease | Spondylolisthesis | StenosisUnited States
-
Ain Shams UniversityActive, not recruitingImmediate Implant PlacementEgypt
-
M3 HealthSão Paulo State UniversityNot yet recruiting
-
SVS Institute of Dental SciencesAzureBio, Madrid, SoainCompleted
-
Florida Orthopaedic InstituteTerminatedFemoral Fractures | Tibial FracturesUnited States